positive

AAMPACT CEO Thomas Fischer exclusive: The mood is positive

The AAMPACT CEO is open about the major challenges facing the independent spare parts and repair market. He believes that…

1 week ago

A new outlet for retail investors? FIND MINING promises to disrupt the industry and strives to achieve $1 billion in revenue by 2025

As Bitcoin resumes its upward trend, FIND MINING will seize new opportunities in cloud computing power in 2025 and target…

3 weeks ago

Bybit TradFi x Crypto Report: Regulatory Tailwinds Drive Coinbase Outperformance Despite Premium Valuation

DUBAI, UAE, July 4, 2025 /PRNewswire/ -- Bybit, the world's second-largest cryptocurrency exchange by trading volume, has released a new…

3 weeks ago

GlucoModicum Reports Positive Clinical Results with its Needle-Free CGM and Advances Toward Market Launch

GlucoModicum Reports Positive Clinical Results with its Needle-Free CGM and Advances Toward Market Launch Comprehensive clinical performance study encompassed 646…

3 weeks ago

Altri to Acquire a Majority Stake in AeoniQ to Scale World’s First Industrial Production of Climate Positive Textile Yarn

ZÜRICH and PORTO, Portugal, July 1, 2025 /PRNewswire/ -- Altri SGPS S.A. (ALTR.LS), a Portuguese-listed leader in sustainable cellulosic pulp…

3 weeks ago

GENESIS MAGMA RACING TAKES POSITIVES FROM FIRST 24 HOURS OF LE MANS PARTICIPATION

Genesis Magma Racing drivers and team members took valuable lessons from first involvement in 24 Hours of Le Mans, working…

1 month ago

Woxsen Among World’s Top 11 in Positive Impact Rating 2025

HYDERABAD, India, June 11, 2025 /PRNewswire/ -- Woxsen University has been recognised once again as a Level 5 'Pioneering' School…

1 month ago

New Potential Treatment Strategy for Brain Metastases and Leptomeningeal Disease: HER3-DXd Shows Promising Results in the Phase II TUXEDO-3 Study for Patients With Limited Therapeutic Options

The TUXEDO-3 trial is the first study to evaluate the intracranial and extracranial efficacy and safety of a novel anti-cancer…

2 months ago

New data show Roches Itovebi significantly extended survival in a certain type of HR-positive advanced breast cancer

The ItovebiTM (inavolisib)-based regimen reduced the risk of death by more than 30% in people with PIK3CA-mutated HR-positive, HER2-negative advanced…

2 months ago